Senores Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg which will be marketed by Dr. Reddy s Laboratories Inc. in the US market".
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Senores Pharmaceuticals' US subsidiary has received approval to launch Deferiprone Tablets (500 mg and 1000 mg) in the US market. The product will be marketed by Dr. Reddy's Laboratories Inc. in the United States. Deferiprone is an iron chelator used in the treatment of iron overload conditions. This marks Senores' entry into the US generics market through a marketing partnership with an established player.
This is a positive development as it opens up US market revenue for Senores through a partnership with Dr. Reddy's, potentially adding a new revenue stream. However, the exact financial impact depends on the commercial terms and market share captured.